B-Cell Non-Hodgkin Lymphoma — Trials

B-Cell Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

6,180 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,757
Recruiting: 906
Ph III recruiting: 103
Growth YoY: +6.8%
Industry share: 27%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (954)

clinicaltrialsPublishedShowing 1,101–1,117 of 1,117 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00063713	VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma	completed	Phase 2	152	Millennium Pharmaceuticals, Inc.INDUSTRY	1	Feb 11, 2008	clinicaltrials
NCT00085696	VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma	completed	Phase 2	66	Millennium Pharmaceuticals, Inc.INDUSTRY	1	Feb 11, 2008	clinicaltrials